Literature DB >> 21724399

The neurologic manifestations of the acute porphyrias.

Neil G Simon1, Geoffrey K Herkes.   

Abstract

The porphyrias are diseases characterised by accumulation of porphyrins and porphyrin precursors owing to enzymatic deficiencies of the haem synthetic pathway. In the acute hepatic porphyrias accumulation of porphyrin precursors, in particular delta-aminolaevulinic acid (ALA), cause dysfunction of the central, peripheral and autonomic nervous systems. This leads to the characteristic clinical findings of abdominal pain, neuropsychiatric symptoms and neuropathy. The exact pathogenic mechanism is not clear but evidence to date suggests both direct toxic effects of ALA and intracellular metabolic derangement contribute to the neurologic disorders. This review explores the mechanisms of neural dysfunction in the acute porphyrias and the resultant clinical features of an acute attack. Crown
Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724399     DOI: 10.1016/j.jocn.2011.01.003

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  18 in total

1.  A Commonly Missed Well Known Entity- Acute Intermittent Porphyria: A Case Report.

Authors:  Smilu Mohanlal; Radha Gulati Ghildiyal; Alpana Kondekar; Poonam Wade; Richa Sinha
Journal:  J Clin Diagn Res       Date:  2016-10-01

2.  Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

Authors:  Vanda Andrade; M Luísa Mateus; M Camila Batoréu; Michael Aschner; Ap Marreilha Dos Santos
Journal:  EC Pharmacol Toxicol       Date:  2017-01-23

Review 3.  Acute hepatic porphyrias: Recommendations for evaluation and long-term management.

Authors:  Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

4.  Psychiatrists' views of the genetic bases of mental disorders and behavioral traits and their use of genetic tests.

Authors:  Robert Klitzman; Kristopher J Abbate; Wendy K Chung; Karen Marder; Ruth Ottman; Katherine Johansen Taber; Cheng-Shiun Leu; Paul S Appelbaum
Journal:  J Nerv Ment Dis       Date:  2014-07       Impact factor: 2.254

5.  Acute intermittent porphyria: A critical diagnosis for favorable outcome.

Authors:  Chhaya Divecha; Milind S Tullu; Akanksha Gandhi; Chandrahas T Deshmukh
Journal:  Indian J Crit Care Med       Date:  2016-07

6.  Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome, Accompanied by Prolonged Vasoconstriction.

Authors:  Tadayuki Takata; Kodai Kume; Yohei Kokudo; Kazuyo Ikeda; Masaki Kamada; Tetsuo Touge; Kazushi Deguchi; Tsutomu Masaki
Journal:  Intern Med       Date:  2017-03-17       Impact factor: 1.271

7.  The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-07

8.  Severe neurologic manifestations in acute intermittent porphyria developed after spine surgery under general anesthesia: a case report.

Authors:  Eun Young Park; Yi Seul Kim; Kyung-Jee Lim; Hye Kyoung Lee; Soo Kyung Lee; Hyun Choi; Mae-Hwa Kang
Journal:  Korean J Anesthesiol       Date:  2014-09-24

9.  A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.

Authors:  Yang Yang; Xiyun Chen; Huijuan Wu; Hua Peng; Wenjing Sun; Bin He; Zhengang Yuan
Journal:  Mol Med Rep       Date:  2020-05-04       Impact factor: 2.952

10.  Posterior Reversible Encephalopathy Syndrome in a Patient with Variegate Porphyria: A Case Report.

Authors:  Faiza Rasheed; Qasim S Mehdi; Shoaib Bhatti; Muhammad Mannan Ali Khan
Journal:  Cureus       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.